Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 16/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | KIT | P10721 | 8/20 | 0.84 |
| ▸ | ABL1 | P00519 | 8/20 | 0.75 |
| ▸ | EGFR | P00533 | 3/20 | 0.74 |
| ▸ | JAK3 | P52333 | 1/20 | 0.74 |
| ▸ | BTK | Q06187 | 1/20 | 0.74 |
| ▸ | ITK | Q08881 | 1/20 | 0.74 |
| ▸ | BCR | P11274 | 6/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.73 |
| ▸ | PRKCA | P17252 | 1/20 | 0.72 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.68 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.68 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.68 |
| ▸ | DDX3X | O00571 | 1/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12627018 | 0.95 | PDGFRA (0.91) | PDGFRAKDRKITABL1EGFR | |
| SCHEMBL12627009 | 0.92 | PDGFRA (0.86) | PDGFRAKDRKITABL1EGFR | |
| SCHEMBL2317193 | 0.90 | PDGFRA (1.00) | PDGFRAKDRKITABL1EGFR | |
| SCHEMBL12627013 | 0.89 | PDGFRA (0.81) | PDGFRAKDRKITABL1EGFR | |
| SCHEMBL805395 | 0.87 | PDGFRA (0.85) | PDGFRAKDRKITABL1EGFR | |
| SCHEMBL27804782 | 0.87 | PDGFRA (0.85) | PDGFRAKDRKITABL1EGFR | |
| SCHEMBL5050327 | 0.86 | PDGFRA (0.89) | PDGFRAKDRKITABL1EGFR | |
| SCHEMBL25281830 | 0.86 | PDGFRA (1.00) | PDGFRAKDRKITABL1EGFR | |
| SCHEMBL29628979 | 0.86 | PDGFRA (1.00) | PDGFRAKDRKITABL1EGFR | |
| SCHEMBL21248036 | 0.86 | PDGFRA (0.84) | PDGFRAKDRKITABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9067929-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067929-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067929-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8242271-B2 | Heterocyclic compounds and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242271-B2 | Heterocyclic compounds and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| EP-2152079-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008151183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008151183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | PDGFRA 3134/4885KDR 3628/4885KIT 1013/4885 |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | PDGFRA 3134/4885KDR 3628/4885KIT 1013/4885 |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, ADK, TTK | PDGFRA 1238/4885KDR 2005/4885KIT 2556/4885 |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | PDGFRA 3134/4885KDR 3628/4885KIT 1013/4885 |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | MAP3K20, ADK, TTK | PDGFRA 1238/4885KDR 2005/4885KIT 2556/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | PDGFRA 1302/4885KDR 2212/4885KIT 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.